Impaired hematopoiesis affects apheresis and CAR T‐cell product composition and treatment response
Transfusion · 2026-07 · 66 (7) · 1375-1389
DOI: 10.1111/trf.70224 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transfusion, online erschienen am 10.04.2026. Verfasst von Hanna Kuhn und 14 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany. Hauptthemen laut MEDLINE: Leukapheresis, Hematopoiesis, T-Lymphocytes, Immunotherapy, Adoptive. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Chimeric antigen receptor (CAR) T‐cell therapy has transformed the treatment of hematologic malignancies, but its success depends on obtaining sufficient CD3 + T‐cell yields during leukapheresis. This can be difficult in heavily pretreated patients, who often show leukopenia and reduced T‐cell fitness.
Methods
We analyzed 166 leukapheresis products from 154 patients undergoing manufacturing of CD19‐directed CAR T‐cells, including 146 from non‐Hodgkin's lymphoma (NHL) and 20 from acute lymphoblastic leukemia (ALL). Collections were performed for commercial CAR T‐cell products (axi‐cel, tisa‐cel, brexu‐cel, liso‐cel; n = 121) and the HD‐CAR‐1 trial with in‐house manufacturing (heidagenlecleucel; n = 45).
Results
In 150/154 patients, a sufficient CD3 + T‐cell yield was achieved by a single leukapheresis. Pre‐apheresis lymphocyte count strongly predicted CD3 + T‐cell yield ( p < .001) and was associated with treatment response ( p = .044). Impaired hematopoiesis, reflected by reduced nucleated cell count ( p < .001), lymphocyte count ( p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.
- Institute of Clinical Transfusion Medicine and Cell Therapy (IKTZ), Heidelberg, Germany.
- Institute of Immunology, University Hospital Heidelberg, Heidelberg, Germany.
ORCID-Profile: Hanna Kuhn, Kiavasch Farid
Zitieren
APA
Kuhn, H., Korell, F., Hückelhoven-Krauss, A., Neuber, B., Stenzinger, M., Ludwig-Husemann, A., Schubert, M. L., Derigs, P., Farid, K., Sauer, T., Sauer, S., Müller-Tidow, C., Dreger, P., Schmitt, M., & Schmitt, A. (2026). Impaired hematopoiesis affects apheresis and CAR T‐cell product composition and treatment response. Transfusion, 66(7), 1375-1389. https://doi.org/10.1111/trf.70224
Vancouver
Kuhn H, Korell F, Hückelhoven-Krauss A, Neuber B, Stenzinger M, Ludwig-Husemann A, et al. Impaired hematopoiesis affects apheresis and CAR T‐cell product composition and treatment response. Transfusion. 2026;66(7):1375-1389. doi:10.1111/trf.70224
BibTeX
@article{Kuhn2026,
author = {Kuhn, Hanna and Korell, Felix and Hückelhoven-Krauss, Angela and Neuber, Brigitte and Stenzinger, Miriam and Ludwig-Husemann, Anita and Schubert, Maria-Luisa and Derigs, Patrick and Farid, Kiavasch and Sauer, Tim and Sauer, Sandra and Müller-Tidow, Carsten and Dreger, Peter and Schmitt, Michael and Schmitt, Anita},
title = {Impaired hematopoiesis affects apheresis and CAR T‐cell product composition and treatment response},
journal = {Transfusion},
year = {2026},
volume = {66},
number = {7},
pages = {1375--1389},
doi = {10.1111/trf.70224}
}
EUVIMED